This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rogers, W. J. Articles by Soto, B. Search for Related Content PubMed PubMed Citation Articles by Rogers, W. J. Articles by Soto, B.

Circulation, Vol 68, 1051-1061, Copyright © 1983 by American Heart Association

ARTICLES

Prospective randomized trial of intravenous and intracoronary streptokinase in acute myocardial infarction

WJ Rogers, JA Mantle, WP Hood Jr, WA Baxley, PL Whitlow, RC Reeves and B Soto

To evaluate the relative thrombolytic efficacy and complications of intracoronary vs high-dose, short-term intravenous streptokinase infusion in patients with acute myocardial infarction, we performed baseline coronary arteriography and then randomly allocated 51 patients with acute myocardial infarction to receive either intracoronary (n = 25) or intravenous (n = 26) streptokinase. Patients getting the drug by the intracoronary route received 240,000 IU of streptokinase into the infarct-related artery over 1 hr, whereas those getting the drug by the intravenous route received either 500,000 IU of streptokinase over 15 min (n = 10) or 1 million IU of streptokinase over 45 min (n = 16). Angiographically observed thrombolysis occurred in 76% (19/25) of the patients receiving intracoronary streptokinase, in 10% (1/10) of the patients receiving 500,000 IU of streptokinase intravenously, and in 44% (7/16) of the patients receiving 1 million IU of streptokinase intravenously. Among patients in whom thrombolysis was observed, mean elapsed time from onset of streptokinase infusion until lysis was 31 +/- 18 min in patients receiving intracoronary streptokinase and 38 +/- 20 min in those receiving intravenous streptokinase (p = NS). Among patients in whom intravenous streptokinase "failed," intracoronary streptokinase in combination with intracoronary guidewire manipulation recanalized only 7% (1/15). Fibrinogen levels within 6 hr after streptokinase were significantly lower in the patients receiving intravenous streptokinase (39 +/- 17 mg/dl) than the levels in those receiving intracoronary streptokinase (88 +/- 70 mg/dl) (p less than .05) but were similar 24 hr after streptokinase in the two groups. Bleeding requiring transfusion occurred in one patient in each group. Thus, in this prospective randomized trial of intracoronary vs intravenous streptokinase, hemorrhagic complications were few, although both regimens produced a systemic lytic state. Although the thrombolytic efficacy of intracoronary streptokinase was superior to that of high-dose, short-term intravenous streptokinase, the higher- dose intravenous regimen (1 million IU over 45 min) achieved thrombolysis in a significant minority (44%) of patients and might be useful therapy for patients not having access to emergency catheterization.

This article has been cited by other articles:

				Intra-arterial Thrombolysis AJNR Am. J. Neuroradiol., September 1, 2001; 22(2007): 18S - 21S. [Full Text] [PDF]

				E. M. Ohman, R. A. Harrington, C. P. Cannon, G. Agnelli, J. A. Cairns, and J.W. Kennedy Intravenous Thrombolysis in Acute Myocardial Infarction Chest, January 1, 2001; 119 (2009): 253S - 277S. [Full Text] [PDF]

				D. Collen Coronary Thrombolysis: Streptokinase or Recombinant Tissue-Type Plasminogen Activator? Ann Intern Med, April 1, 1990; 112(7): 529 - 538. [Abstract] [PDF]

				D. C. Babalis, G. N. Boutos, E. K. Iliodromitis, A. K. Trovas, and E. M. Vorides Precordial ECG Mapping in Acute Myocardial Infarction (AMI) After Intravenous Infusion of Streptokinase (s) Angiology, December 1, 1989; 40(12): 1040 - 1047. [Abstract] [PDF]

				P. F. Miller, B. R. Brodie, R. A. Weintraub, E. J. LeBauer, J. D. Katz, T. D. Stuckey, and C. J. Hansen Emergency Coronary Angioplasty for Acute Myocardial Infarction: Results From a Community Hospital Arch Intern Med, September 1, 1987; 147(9): 1565 - 1570. [Abstract] [PDF]

				D. H. Miller, P. Kligfield, T. L. Schreiber, and J. S. Borer Relationship of Prior Myocardial Infarction to False-positive Electrocardiographic Diagnosis of Acute Injury in Patients With Chest Pain Arch Intern Med, February 1, 1987; 147(2): 257 - 261. [Abstract] [PDF]

				V. J. MARDER, R. L. ROTHBARD, P. G. FITZPATRICK, and C. W. FRANCIS Rapid Lysis of Coronary Artery Thrombi with Anisoylated Plasminogen: Streptokinase Activator Complex: Treatment by Bolus Intravenous Injection Ann Intern Med, March 1, 1986; 104(3): 304 - 310. [Abstract] [PDF]

				E. J. TOPOL, W. R. BELL, and M. L. WEISFELDT Coronary Thrombolysis with Recombinant Tissue-Type Plasminogen Activator: A Hematologic and Pharmacologic Study Ann Intern Med, December 1, 1985; 103(6_Part_1): 837 - 843. [Abstract] [PDF]

				Thrombolysis for Evolving Myocardial Infarction Ann Intern Med, September 1, 1985; 103(3): 463 - 469. [Abstract] [PDF]